(E)-1-(4-methoxybenzyl)-N'-(5-chloro-2-oxoindolin-3-ylidene)-1H-1,2,3-triazole-4-carbohydrazide

ID: ALA4559911

PubChem CID: 155557998

Max Phase: Preclinical

Molecular Formula: C19H15ClN6O3

Molecular Weight: 410.82

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4ccc(Cl)cc43)nn2)cc1

Standard InChI:  InChI=1S/C19H15ClN6O3/c1-29-13-5-2-11(3-6-13)9-26-10-16(22-25-26)18(27)24-23-17-14-8-12(20)4-7-15(14)21-19(17)28/h2-8,10H,9H2,1H3,(H,24,27)(H,21,23,28)

Standard InChI Key:  FJRWCMVXYOJZIK-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
   25.9197  -12.1099    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.6653  -11.3291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8481  -11.3291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.2567  -12.5878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.5983  -12.1082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.8558  -12.4387    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.7705  -13.2487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.4338  -13.7269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1737  -13.3937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.1454  -10.6678    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.3665  -10.6689    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.1666   -9.7072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.1655  -10.5309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.8777  -10.9440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5873  -10.5304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5845   -9.7036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.8759   -9.2983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.4533  -10.9430    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.7418  -10.5297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.2948   -9.2923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0082   -9.6983    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.1003  -10.5137    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.9044  -10.6806    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.3145   -9.9672    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7612   -9.3621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1331   -9.9631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.5452  -10.6729    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.5382   -9.2534    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.0246  -13.5823    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  3  5  1  0
  1  2  1  0
  4  1  1  0
  2  3  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  2 10  2  0
  3 11  2  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 12  1  0
 13 18  1  0
 18 19  1  0
 16 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 21  1  0
 24 26  1  0
 26 27  1  0
 26 28  2  0
 27 11  1  0
  7 29  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4559911

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 410.82

Molecular Weight (Monoisotopic): 410.0894

AlogP: 2.07

#Rotatable Bonds: 5

Polar Surface Area: 110.50

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.59

CX Basic pKa: ┄

CX LogP: 2.83

CX LogD: 2.81

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.63

Np Likeness Score: -1.97

References

1. Aneja B, Khan NS, Khan P, Queen A, Hussain A, Rehman MT, Alajmi MF, El-Seedi HR, Ali S, Hassan MI, Abid M..  (2019)  Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis.,  163  [PMID:30579124] [10.1016/j.ejmech.2018.12.026]

2. Klaeger, Susan S and 47 more authors.  2017-12-01  The target landscape of clinical kinase drugs.  [PMID:29191878]

3. Narayan, Satya S and 7 more authors.  2019-01-01  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.  [PMID:30384048]

Source

Source(1):

• Scientific Literature